|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.780 HKD | -2.26% |
|
-5.12% | -7.71% |
| 14/05 | Concord Healthcare Completes HK$68 Million Convertible Bond Issue to CSPC Pharma Unit | MT |
| 11/05 | CSPC Pharmaceutical's Tumor Drug Gets Breakthrough Therapy Designation in China | MT |
| Capitalization | 8.89TCr 1.14TCr 977.48Cr 893.73Cr 852.71Cr 1.56TCr 1,09000Cr 1.59TCr 11TCr 4.15TCr 52TCr 4.26TCr 4.17TCr 1,80200Cr | P/E ratio 2026 * |
11.6x | P/E ratio 2027 * | 13.7x |
|---|---|---|---|---|---|
| Enterprise value | 7.5TCr 957.34Cr 823.79Cr 753.2Cr 718.64Cr 1.32TCr 92TCr 1.34TCr 9.04TCr 3.5TCr 44TCr 3.59TCr 3.52TCr 1,51900Cr | EV / Sales 2026 * |
2.16x | EV / Sales 2027 * | 2.15x |
| Free-Float |
68.05% | Yield 2026 * |
5.27% | Yield 2027 * | 4.35% |
| 1 day | -2.26% | ||
| 1 week | -5.12% | ||
| Current month | -7.49% | ||
| 1 month | -13.17% | ||
| 3 months | -24.10% | ||
| 6 months | -1.14% | ||
| Current year | -7.71% |
| 1 week | 7.64 |  | 8.29 |
| 1 month | 7.64 | | 9.08 |
| Current year | 7.64 | | 10.96 |
| 1 year | 5.83 | | 11.63 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 12.68 |
| 10 years | 3.37 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Cai
CEO | Chief Executive Officer | 46 | 19/12/2025 |
Qing Jie Wei
COO | Chief Operating Officer | 56 | 19/12/2025 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 44 | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 26/08/2011 |
Huai Yu Wang
BRD | Director/Board Member | 63 | 01/10/2010 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 20/01/2012 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | -5.12% | +32.09% | +3.32% | 1.14TCr | |
| -0.00% | +5.95% | +32.68% | +129.71% | 90TCr | |
| -1.77% | +2.44% | +49.81% | +42.59% | 55TCr | |
| -0.18% | +4.39% | +14.33% | +46.77% | 37TCr | |
| +0.88% | +2.38% | +24.30% | +13.90% | 33TCr | |
| -0.10% | +2.93% | +27.56% | +28.14% | 28TCr | |
| -0.79% | +2.16% | +31.97% | +14.32% | 28TCr | |
| -1.79% | 0.00% | +46.44% | -2.95% | 28TCr | |
| +0.91% | +3.07% | -29.86% | -47.97% | 21TCr | |
| -2.22% | -1.62% | +19.79% | +45.01% | 18TCr | |
| Average | -0.73% | +1.56% | +24.91% | +27.29% | 33.75TCr | |
| Weighted average by Cap. | -0.51% | +3.14% | +28.75% | +50.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.47TCr 442.86Cr 381.08Cr 348.43Cr 332.44Cr 609.45Cr 42TCr 619.52Cr 4.18TCr 1.62TCr 20TCr 1.66TCr 1.63TCr 70TCr | 3.42TCr 436.14Cr 375.3Cr 343.15Cr 327.4Cr 600.2Cr 42TCr 610.12Cr 4.12TCr 1.59TCr 20TCr 1.64TCr 1.6TCr 69TCr |
| Net income | 748.14Cr 96Cr 82Cr 75Cr 72Cr 131.48Cr 9.17TCr 133.66Cr 901.86Cr 348.98Cr 4.35TCr 358.55Cr 350.87Cr 15TCr | 643.92Cr 82Cr 71Cr 65Cr 62Cr 113.17Cr 7.89TCr 115.04Cr 776.23Cr 300.37Cr 3.75TCr 308.61Cr 302Cr 13TCr |
| Net Debt | -1.4TCr -178.61Cr -153.7Cr -140.53Cr -134.08Cr -245.8Cr -17TCr -249.86Cr -1.69TCr -652.4Cr -8.13TCr -670.29Cr -655.93Cr -28TCr | -1.56TCr -199.04Cr -171.28Cr -156.6Cr -149.41Cr -273.92Cr -19TCr -278.44Cr -1.88TCr -727.03Cr -9.07TCr -746.97Cr -730.97Cr -32TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 7.780 $ | -2.26% | 7,60,56,520 |
| 14/26/14 | 7.960 $ | -1.12% | 8,17,69,140 |
| 13/26/13 | 8.050 $ | -0.74% | 7,70,12,500 |
| 12/26/12 | 8.110 $ | -1.10% | 12,34,92,800 |
| 11/26/11 | 8.200 $ | 0.00% | 6,70,37,570 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition